Literature DB >> 20172579

Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5.

Robert A Ogert1, Yan Hou, Lei Ba, Lisa Wojcik, Ping Qiu, Nicholas Murgolo, Jose Duca, Lisa M Dunkle, Robert Ralston, John A Howe.   

Abstract

The HIV-1 CCR5 co-receptor is a member of the chemokine receptor family of G-protein coupled receptors; for which a number of small molecule antagonists, such as vicriviroc (VCV), have been developed to inhibit HIV-1 R5-tropic replication. In this study, we analyzed an HIV-1 subtype D envelope gene from a clinical trial subject who developed complete resistance to VCV. The HIV-1 resistant envelope has six predominant amino acid changes in the V3 loop, together with one change in the C4 domain of gp120, which are fully responsible for the resistance phenotype. V3 loop mutations Q315E and R321G are essential for resistance to VCV, whereas E328K and G429R in C4 contribute significantly to the infectivity of the resistant variant. Collectively, these amino acid changes influenced the interaction of gp120 with both the N-terminus and ECL2 region of CCR5. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20172579     DOI: 10.1016/j.virol.2010.01.037

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  26 in total

Review 1.  Drug resistance in HIV-1.

Authors:  Daniel R Kuritzkes
Journal:  Curr Opin Virol       Date:  2011-12       Impact factor: 7.090

2.  Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists.

Authors:  Timothy J Henrich; Nicolas R P Lewine; Sun-Hee Lee; Suhas S P Rao; Reem Berro; Roy M Gulick; John P Moore; Athe M N Tsibris; Daniel R Kuritzkes
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

3.  Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages.

Authors:  Kieran Cashin; Michael Roche; Jasminka Sterjovski; Anne Ellett; Lachlan R Gray; Anthony L Cunningham; Paul A Ramsland; Melissa J Churchill; Paul R Gorry
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

4.  Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors.

Authors:  Thomas J Ketas; Sophie Holuigue; Katie Matthews; John P Moore; Per Johan Klasse
Journal:  Virology       Date:  2011-10-22       Impact factor: 3.616

5.  Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors.

Authors:  Reem Berro; Per Johan Klasse; Danny Lascano; Ayanna Flegler; Kirsten A Nagashima; Rogier W Sanders; Thomas P Sakmar; Thomas J Hope; John P Moore
Journal:  J Virol       Date:  2011-06-15       Impact factor: 5.103

6.  V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc.

Authors:  Reem Berro; Per Johan Klasse; Martin R Jakobsen; Paul R Gorry; John P Moore; Rogier W Sanders
Journal:  Virology       Date:  2012-03-16       Impact factor: 3.616

7.  HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism.

Authors:  Michael Roche; Martin R Jakobsen; Jasminka Sterjovski; Anne Ellett; Filippo Posta; Benhur Lee; Becky Jubb; Mike Westby; Sharon R Lewin; Paul A Ramsland; Melissa J Churchill; Paul R Gorry
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

Review 8.  CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV.

Authors:  Michelle B Kim; Kyle E Giesler; Yesim A Tahirovic; Valarie M Truax; Dennis C Liotta; Lawrence J Wilson
Journal:  Expert Opin Investig Drugs       Date:  2016-12       Impact factor: 6.206

9.  CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells.

Authors:  Olga Latinovic; Marvin Reitz; Nhut M Le; James S Foulke; Gerd Fätkenheuer; Clara Lehmann; Robert R Redfield; Alonso Heredia
Journal:  Virology       Date:  2011-01-12       Impact factor: 3.616

10.  Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5.

Authors:  Hamid Salimi; Michael Roche; Nicholas Webb; Lachlan R Gray; Kelechi Chikere; Jasminka Sterjovski; Anne Ellett; Steve L Wesselingh; Paul A Ramsland; Benhur Lee; Melissa J Churchill; Paul R Gorry
Journal:  J Leukoc Biol       Date:  2012-10-17       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.